Replies to post #5990 on GTC Biotherapeutics (fka GTCB)

[ghmm]

I notice that investors tend to think a company is an ideal buyout candidate by company xyz for reasons 1,2,3 when they themselves see it as extremely undervalued. I am certainly guilty of this as well!

I've noticed the next Biotech buyout is rarely one I saw coming and often the acquirer is buying not when the stock is at a (relative) bottom.

If you like the company and your confident in your DD then while it may be frustrating at times (perhaps long periods) to see it appear undervalued the Buffet (or was it Graham?) comment about polling (short-term) vs. weighing (long-term) is good to remember. Of course if your a short-term trader then obviously this is of little consolation.

[Lewis R Goudy]

You remind me of a mother cat swatting her kittens after
patiently waiting for them to find something else to play
with besides her tail so she can get some sleep the better
to make them some more milk. I posted a testy remark a little
while ago but it didn't appear. Maybe you deleted it but the
post numbers show no gap so maybe it fell in the bit bucket
enroute. You already addressed the first part (about the
predictive power of Dr. Gray's accession to the board re pps).
I gently reiterate the second part: close and prolix analysis
of minute intraday price fluctuations, far from being--as has
here been claimed--interesting, is sterile and stultifying, no
less than the traffic which casts Termeer as eminence grise.

>nothing happened after Dr. Lawton came along<
The poster confounds "material development" and "publicly discosed material development". On my view the notions are properly distinguished rather than identified.

Perhaps the antsy impatience stems from the reminder of
mortality that hanging a new calendar brings.

[rkrw]

If Genz takes out gtcb will Cox take over for Termeer? Would be a double win for genz, get gtcb cheap and upgrade at ceo with Cox.